48:
90:
335:
bone marrow transplants and liver transplants. The highest rates of PTLD are seen with lung and heart transplants, which is primarily due to the need for higher levels of immunosuppression. The incidence of PTLD is highest in the first year after transplantation; roughly 80 percent of cases after transplant occur in the first year. Transplantation of unmatched or mismatched HLA bone marrow also increase the risk of PTLD.
237:
334:
PTLD is the second most common malignancy that occurs as a complication following solid organ transplantation (skin cancer is the most common). Less commonly, PTLD occurs after hematopoietic stem cell transplantation. The incidence varies by the type of transplantation: the lowest rates are seen with
138:
Symptoms of PTLD are highly variable and nonspecific, and may include fever, weight loss, night sweats, and fatigue. Symptoms may be similar to those seen in infectious mononucleosis (caused by EBV). Pain or discomfort may result from lymphadenopathy or mass effect from growing tumors. Dysfunction
338:
The main risk factors for PTLD are the degree of immune suppression and the presence of
Epstein-Barr virus. Specifically, higher levels of T cell immunosuppression increase the risk PTLD. Individuals who have never been infected by the Epstein-Barr virus (EBV negative) who receive an organ from a
297:
Definitive diagnosis is achieved by biopsying the involved tissue, which will reveal lymphoproliferative neoplasia. Most lesions will show malignant B cells, whereas a minority will show T cell neoplasia. CT imaging may show enlarged lymph nodes or a focal mass. PET scan may be helpful in the
142:
Laboratory findings may show abnormally low white blood cell, red cell counts, and platelet counts. In addition, serum uric acid and lactate dehydrogenase levels may be elevated, while serum calcium levels may be decreased. All of these findings together can suggest tumor lysis syndrome.
110:
proliferation due to therapeutic immunosuppression after organ transplantation. These patients may develop infectious mononucleosis-like lesions or polyclonal polymorphic B-cell hyperplasia. Some of these B cells may undergo mutations which will render them malignant, giving rise to a
301:
Neurologic symptoms, such as confusion or focal weakness, which may suggest involvement of the nervous system. This may be evaluated with an MRI of the brain with gadolinium based contrast and lumbar spinal tap with testing of the cerebral spinal fluid for EBV viral levels.
47:
305:
The presence of respiratory symptoms, such as cough or shortness of breath, in the setting of immunosuppression may suggest infection. Opportunistic infections may present in a similar fashion to PTLD. Evaluation with sputum culture for bacteria,
900:
522:
510:
2230:
1974:
258:
1528:
2309:
339:
donor with prior EBV infection are 24 times more likely to develop PTLD. Similarly, CMV mismatching (with a CMV negative recipient from a CMV positive donor) increases the risk of PTLD.
1015:
1645:
537:
2235:
2044:
2258:
1610:
608:
2000:
1251:
1339:
2203:
2242:
1788:
1533:
1667:
452:"Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial"
1768:
1566:
2192:
1866:
1420:
671:
174:
in adolescents, which is otherwise asymptomatic in children during their childhood. However, in immunosuppressed transplant patients, the lack of
2039:
1858:
1409:
2187:
298:
evaluation, which may show an increase in metabolic activity (PET avid) lesion, potentially guiding decisions on where to direct biopsies.
118:
In some patients, the malignant cell clone can become the dominant proliferating cell type, leading to frank lymphoma, a group of B cell
2143:
1763:
1561:
1445:
1113:
994:
989:
601:
2034:
2299:
1332:
658:
284:
326:
and may be fatal. A phase 2 study of adoptively transferred EBV-specific T cells demonstrated high efficacy with minimal toxicity.
1995:
920:
905:
636:
1034:
2225:
2217:
2076:
1954:
1893:
1879:
1773:
1714:
1551:
1477:
1039:
1010:
984:
594:
262:
2273:
2183:
2133:
2029:
1758:
1542:
915:
895:
17:
2165:
2071:
2054:
1862:
1416:
1325:
953:
880:
2106:
1979:
1685:
958:
393:"Epstein-Barr Virus-related post-transplant lymphoproliferative disorders: pathogenetic insights for targeted therapy"
247:
2021:
963:
819:
741:
711:
266:
251:
1909:
1750:
1672:
1306:
845:
716:
323:
2111:
1939:
910:
736:
209:
204:
further increases the risk of developing post-transplant lymphoproliferative disorder. Such antibodies include
171:
1577:
1077:
1022:
773:
681:
205:
2128:
1679:
322:
medication, and can also be treated with addition of anti-viral therapy. In some cases it will progress to
156:
66:
2005:
1984:
1898:
1301:
1286:
1207:
1027:
885:
768:
763:
758:
721:
2137:
1727:
1621:
1291:
1228:
1175:
1139:
1067:
748:
726:
706:
617:
1700:
1523:
219:
Polyclonal PTLD may form tumor masses and present with symptoms due to a mass effect, e.g. symptoms of
1934:
1546:
1457:
1098:
855:
731:
696:
201:
89:
1734:
1518:
1488:
1191:
686:
648:
643:
631:
526:
139:
may occur in organs affected by PTLD. Lung or heart involvement may result in shortness of breath.
2198:
1062:
2304:
2278:
1948:
1929:
1918:
1708:
1598:
1513:
1296:
1276:
1271:
1170:
1072:
824:
545:
473:
414:
373:
319:
220:
123:
78:
2048:
1827:
1695:
1594:
1317:
1118:
676:
463:
450:
Haque T, Wilkie GM, Jones MM, Higgins CD, Urquhart G, Wingate P, et al. (August 2007).
404:
365:
356:
Gottschalk S, Rooney CM, Heslop HE (2005). "Post-transplant lymphoproliferative disorders".
127:
1821:
1816:
1625:
1509:
1375:
1370:
1103:
943:
801:
783:
701:
691:
369:
2268:
1165:
1082:
875:
811:
531:
160:
178:
immunosurveillance can lead to the proliferation of these EBV-infected B-lymphocytes.
2293:
2175:
1874:
1783:
1739:
1556:
1430:
1233:
1223:
1144:
1108:
938:
796:
791:
753:
666:
432:
409:
392:
1778:
1440:
1160:
1134:
574:
468:
451:
1452:
1238:
890:
829:
236:
186:
152:
550:
1348:
182:
83:
55:
569:
59:
477:
418:
377:
223:. Monoclonal forms of PTLD tend to form a disseminated malignant lymphoma.
2263:
2091:
1802:
1365:
1352:
1281:
968:
197:
164:
119:
112:
70:
586:
502:
1811:
514:
190:
175:
107:
62:
193:
function, and can prevent the control of the B cell proliferation.
1634:
1499:
1483:
310:, and acid fast bacilli, and fungal infections are often helpful.
2097:
1991:
1970:
1888:
1630:
1605:
1585:
1581:
1468:
1386:
1381:
948:
213:
1321:
590:
189:), used as immunosuppressants in organ transplantation inhibit
1837:
1832:
1722:
230:
318:
PTLD may spontaneously regress on reduction or cessation of
1975:
Non-mycosis fungoides CD30â cutaneous large T-cell lymphoma
170:
In immunocompetent patients, Epstein-Barr virus can cause
18:
Post-transplant lymphoproliferative disorder, pleomorphic
151:
The disease is an uncontrolled proliferation of B cell
492:
2251:
2216:
2174:
2156:
2120:
2090:
2063:
2018:
1963:
1917:
1908:
1848:
1810:
1801:
1749:
1659:
1620:
1576:
1498:
1467:
1429:
1408:
1397:
1364:
1264:
1216:
1200:
1184:
1153:
1127:
1091:
1055:
1048:
1003:
977:
929:
864:
838:
810:
782:
657:
624:
560:
496:
77:
37:
32:
2045:Peripheral T-cell lymphoma not otherwise specified
1867:Precursor T acute lymphoblastic leukemia/lymphoma
1421:Precursor B acute lymphoblastic leukemia/lymphoma
1611:Nodular lymphocyte predominant Hodgkin lymphoma
1252:List of organ transplant donors and recipients
2001:Secondary cutaneous CD30+ large-cell lymphoma
1333:
602:
65:showing infiltrating lymphocytes infected by
8:
1691:Post-transplant lymphoproliferative disorder
1646:immunoproliferative immunoglobulin disorders
851:Post-transplant lymphoproliferative disorder
100:Post-transplant lymphoproliferative disorder
33:Post-transplant lymphoproliferative disorder
2204:Diffuse infiltrative lymphocytosis syndrome
265:. Unsourced material may be challenged and
196:Depletion of T cells by use of anti-T cell
2243:Jessner lymphocytic infiltrate of the skin
1914:
1845:
1807:
1789:Primary cutaneous follicle center lymphoma
1534:Primary cutaneous follicle center lymphoma
1405:
1394:
1361:
1340:
1326:
1318:
1052:
609:
595:
587:
493:
391:Nourse JP, Jones K, Gandhi MK (May 2011).
88:
46:
29:
467:
408:
285:Learn how and when to remove this message
1769:Primary cutaneous marginal zone lymphoma
1567:Primary cutaneous marginal zone lymphoma
2231:with bandlike and perivascular patterns
2193:Autoimmune lymphoproliferative syndrome
348:
2310:EpsteinâBarr virusâassociated diseases
2040:Enteropathy-associated T-cell lymphoma
7:
2188:X-linked lymphoproliferative disease
370:10.1146/annurev.med.56.082103.104727
263:adding citations to reliable sources
2144:Large granular lymphocytic leukemia
1764:Intravascular large B-cell lymphoma
995:Canadian Society of Transplantation
990:American Society of Transplantation
397:American Journal of Transplantation
200:in the prevention or treatment of
25:
181:However, calcineurin inhibitors (
921:United Network for Organ Sharing
906:National Transplant Organization
410:10.1111/j.1600-6143.2011.03499.x
235:
163:, an endogenous, pro-regulatory
1996:CD30+ cutaneous T-cell lymphoma
1035:Organ transplantation in Israel
2226:Cutaneous lymphoid hyperplasia
2218:Cutaneous lymphoid hyperplasia
2077:Adult T-cell leukemia/lymphoma
1955:Adult T-cell leukemia/lymphoma
1894:Anaplastic large-cell lymphoma
1774:Primary cutaneous immunocytoma
1715:Splenic marginal zone lymphoma
1040:Organ transplantation in Japan
1011:Organ transplantation in China
985:American Society of Nephrology
1:
2274:Lymphoproliferative disorders
2184:Lymphoproliferative disorders
2134:Extranodal NK-T-cell lymphoma
2006:Lymphomatoid papulosis type A
1985:Lymphomatoid papulosis type B
1899:Lymphomatoid papulosis type A
1759:Diffuse large B-cell lymphoma
916:Trillium Gift of Life Network
896:National Marrow Donor Program
2166:Acute biphenotypic leukaemia
2055:Subcutaneous T-cell lymphoma
954:Halachic Organ Donor Society
881:Gift of Life Marrow Registry
469:10.1182/blood-2006-12-063008
167:, has also been implicated.
2107:Aggressive NK-cell leukemia
1980:Pleomorphic T-cell lymphoma
1686:Lymphomatoid granulomatosis
959:Kidney Foundation of Canada
2326:
1016:harvesting from Falun Gong
964:National Kidney Foundation
820:Non-heart-beating donation
1360:
1247:
846:Graft-versus-host disease
358:Annual Review of Medicine
159:(EBV). Production of an
106:) is the name given to a
54:
45:
2300:Transplantation medicine
2259:Hematological malignancy
2112:Blastic NK cell lymphoma
1940:Granulomatous slack skin
1696:Classic Hodgkin lymphoma
1595:Classic Hodgkin lymphoma
911:NHS Blood and Transplant
172:infectious mononucleosis
1287:Immunosuppressive drugs
1023:Organ donation in India
155:latently infected with
1307:Frankenstein's monster
1302:Total body irradiation
1028:Gurgaon kidney scandal
886:Human Tissue Authority
324:non-Hodgkin's lymphoma
2138:Angiocentric lymphoma
1728:AIDS-related lymphoma
1552:Splenic marginal zone
1292:Lung allocation score
1229:Jean-Michel Dubernard
618:Organ transplantation
2236:with nodular pattern
1935:Pagetoid reticulosis
1547:marginal zone B-cell
1099:J. Hartwell Harrison
856:Transplant rejection
437:webpath.med.utah.edu
308:Pneumocystis carinii
259:improve this section
202:transplant rejection
1735:Helicobacter pylori
1562:Nodal marginal zone
1489:Hairy cell leukemia
1355:and related disease
1208:André van der Merwe
1192:Richard C. Lillehei
865:Transplant networks
649:Xenotransplantation
644:Autotransplantation
632:Allotransplantation
126:patients following
2279:Lymphoid leukemias
2199:Leukemoid reaction
2035:Angioimmunoblastic
1701:Burkitt's lymphoma
1063:Christiaan Barnard
659:Organs and tissues
561:External resources
157:EpsteinâBarr virus
134:Signs and symptoms
67:EpsteinâBarr virus
2287:
2286:
2212:
2211:
2152:
2151:
2086:
2085:
2014:
2013:
1930:Mycosis fungoides
1797:
1796:
1655:
1654:
1599:Nodular sclerosis
1514:follicular B cell
1315:
1314:
1297:Machine perfusion
1277:Edmonton protocol
1272:Biomedical tissue
1260:
1259:
1171:Vladimir Demikhov
1073:Adrian Kantrowitz
825:Organ procurement
584:
583:
433:"Hematopathology"
320:immunosuppressant
295:
294:
287:
221:bowel obstruction
216:(muromonab-CD3).
97:
96:
27:Medical condition
16:(Redirected from
2317:
2049:Lennert lymphoma
1915:
1846:
1808:
1673:Primary effusion
1406:
1395:
1362:
1342:
1335:
1328:
1319:
1119:Michael Woodruff
1053:
784:Medical grafting
611:
604:
597:
588:
494:
482:
481:
471:
462:(4): 1123â1131.
447:
441:
440:
429:
423:
422:
412:
388:
382:
381:
353:
290:
283:
279:
276:
270:
239:
231:
128:organ transplant
124:immunosuppressed
93:
92:
50:
30:
21:
2325:
2324:
2320:
2319:
2318:
2316:
2315:
2314:
2290:
2289:
2288:
2283:
2247:
2208:
2170:
2158:
2148:
2116:
2095:
2082:
2059:
2020:
2010:
1959:
1904:
1852:
1850:
1825:
1820:
1814:
1793:
1745:
1651:
1628:
1616:
1572:
1510:germinal center
1494:
1463:
1425:
1401:
1399:
1379:
1374:
1368:
1356:
1346:
1316:
1311:
1256:
1243:
1212:
1196:
1180:
1149:
1123:
1104:John P. Merrill
1087:
1044:
999:
978:Joint societies
973:
944:Blood Cancer UK
931:
925:
868:
866:
860:
834:
806:
802:Vascular bypass
778:
653:
620:
615:
585:
580:
579:
556:
555:
505:
491:
486:
485:
449:
448:
444:
431:
430:
426:
390:
389:
385:
355:
354:
350:
345:
332:
316:
291:
280:
274:
271:
256:
240:
229:
149:
136:
87:
28:
23:
22:
15:
12:
11:
5:
2323:
2321:
2313:
2312:
2307:
2302:
2292:
2291:
2285:
2284:
2282:
2281:
2276:
2271:
2269:Leukemia cutis
2266:
2261:
2255:
2253:
2249:
2248:
2246:
2245:
2240:
2239:
2238:
2233:
2222:
2220:
2214:
2213:
2210:
2209:
2207:
2206:
2201:
2196:
2190:
2180:
2178:
2172:
2171:
2169:
2168:
2162:
2160:
2154:
2153:
2150:
2149:
2147:
2146:
2141:
2124:
2122:
2118:
2117:
2115:
2114:
2109:
2103:
2101:
2088:
2087:
2084:
2083:
2081:
2080:
2067:
2065:
2061:
2060:
2058:
2057:
2052:
2042:
2037:
2032:
2026:
2024:
2016:
2015:
2012:
2011:
2009:
2008:
2003:
1998:
1988:
1987:
1982:
1977:
1967:
1965:
1961:
1960:
1958:
1957:
1949:SĂ©zary disease
1943:
1942:
1937:
1932:
1923:
1921:
1912:
1906:
1905:
1903:
1902:
1896:
1884:
1883:
1880:Prolymphocytic
1870:
1856:
1854:
1843:
1842:
1841:
1835:
1805:
1799:
1798:
1795:
1794:
1792:
1791:
1786:
1781:
1776:
1771:
1766:
1761:
1755:
1753:
1747:
1746:
1744:
1743:
1731:
1719:
1718:
1717:
1705:
1704:
1703:
1698:
1693:
1688:
1676:
1663:
1661:
1657:
1656:
1653:
1652:
1650:
1649:
1640:
1638:
1618:
1617:
1615:
1614:
1602:
1591:
1589:
1574:
1573:
1571:
1570:
1564:
1559:
1554:
1538:
1537:
1531:
1526:
1521:
1505:
1503:
1496:
1495:
1493:
1492:
1480:
1478:Prolymphocytic
1474:
1472:
1465:
1464:
1462:
1461:
1449:
1436:
1434:
1427:
1426:
1424:
1414:
1412:
1403:
1392:
1391:
1390:
1358:
1357:
1347:
1345:
1344:
1337:
1330:
1322:
1313:
1312:
1310:
1309:
1304:
1299:
1294:
1289:
1284:
1279:
1274:
1268:
1266:
1265:Related topics
1262:
1261:
1258:
1257:
1255:
1254:
1248:
1245:
1244:
1242:
1241:
1236:
1231:
1226:
1220:
1218:
1214:
1213:
1211:
1210:
1204:
1202:
1198:
1197:
1195:
1194:
1188:
1186:
1182:
1181:
1179:
1178:
1176:James D. Hardy
1173:
1168:
1166:Joel D. Cooper
1163:
1157:
1155:
1151:
1150:
1148:
1147:
1142:
1140:James D. Hardy
1137:
1131:
1129:
1125:
1124:
1122:
1121:
1116:
1114:Elizabeth Ward
1111:
1106:
1101:
1095:
1093:
1089:
1088:
1086:
1085:
1083:Norman Shumway
1080:
1075:
1070:
1068:James D. Hardy
1065:
1059:
1057:
1050:
1046:
1045:
1043:
1042:
1037:
1032:
1031:
1030:
1020:
1019:
1018:
1007:
1005:
1001:
1000:
998:
997:
992:
987:
981:
979:
975:
974:
972:
971:
966:
961:
956:
951:
946:
941:
935:
933:
927:
926:
924:
923:
918:
913:
908:
903:
898:
893:
888:
883:
878:
876:Eurotransplant
872:
870:
867:and government
862:
861:
859:
858:
853:
848:
842:
840:
836:
835:
833:
832:
827:
822:
816:
814:
812:Organ donation
808:
807:
805:
804:
799:
794:
788:
786:
780:
779:
777:
776:
771:
766:
761:
756:
751:
746:
745:
744:
734:
729:
724:
719:
714:
709:
704:
699:
694:
689:
684:
679:
674:
669:
663:
661:
655:
654:
652:
651:
646:
641:
640:
639:
628:
626:
622:
621:
616:
614:
613:
606:
599:
591:
582:
581:
578:
577:
565:
564:
562:
558:
557:
554:
553:
542:
534:
519:
506:
501:
500:
498:
497:Classification
490:
489:External links
487:
484:
483:
442:
424:
403:(5): 888â895.
383:
347:
346:
344:
341:
331:
328:
315:
312:
293:
292:
243:
241:
234:
228:
225:
161:interleukin-10
148:
145:
135:
132:
95:
94:
81:
75:
74:
52:
51:
43:
42:
39:
35:
34:
26:
24:
14:
13:
10:
9:
6:
4:
3:
2:
2322:
2311:
2308:
2306:
2303:
2301:
2298:
2297:
2295:
2280:
2277:
2275:
2272:
2270:
2267:
2265:
2262:
2260:
2257:
2256:
2254:
2250:
2244:
2241:
2237:
2234:
2232:
2229:
2228:
2227:
2224:
2223:
2221:
2219:
2215:
2205:
2202:
2200:
2197:
2194:
2191:
2189:
2185:
2182:
2181:
2179:
2177:
2176:Lymphocytosis
2173:
2167:
2164:
2163:
2161:
2155:
2145:
2142:
2139:
2135:
2131:
2130:
2126:
2125:
2123:
2119:
2113:
2110:
2108:
2105:
2104:
2102:
2099:
2093:
2089:
2078:
2074:
2073:
2069:
2068:
2066:
2062:
2056:
2053:
2050:
2046:
2043:
2041:
2038:
2036:
2033:
2031:
2030:Hepatosplenic
2028:
2027:
2025:
2023:
2017:
2007:
2004:
2002:
1999:
1997:
1993:
1990:
1989:
1986:
1983:
1981:
1978:
1976:
1972:
1969:
1968:
1966:
1962:
1956:
1953:
1952:
1951:
1950:
1947:
1941:
1938:
1936:
1933:
1931:
1928:
1925:
1924:
1922:
1920:
1916:
1913:
1911:
1907:
1900:
1897:
1895:
1891:
1890:
1886:
1885:
1881:
1877:
1876:
1875:prolymphocyte
1872:
1871:
1868:
1864:
1860:
1857:
1855:
1847:
1844:
1839:
1836:
1834:
1831:
1830:
1829:
1823:
1818:
1813:
1809:
1806:
1804:
1800:
1790:
1787:
1785:
1784:Plasmacytosis
1782:
1780:
1777:
1775:
1772:
1770:
1767:
1765:
1762:
1760:
1757:
1756:
1754:
1752:
1748:
1741:
1740:MALT lymphoma
1737:
1736:
1732:
1729:
1725:
1724:
1720:
1716:
1713:
1712:
1711:
1710:
1706:
1702:
1699:
1697:
1694:
1692:
1689:
1687:
1684:
1683:
1682:
1681:
1677:
1674:
1670:
1669:
1665:
1664:
1662:
1658:
1648:
1647:
1642:
1641:
1639:
1636:
1632:
1627:
1623:
1619:
1612:
1608:
1607:
1603:
1600:
1596:
1593:
1592:
1590:
1587:
1583:
1579:
1575:
1568:
1565:
1563:
1560:
1558:
1555:
1553:
1549:
1548:
1544:
1543:marginal zone
1540:
1539:
1535:
1532:
1530:
1527:
1525:
1522:
1520:
1516:
1515:
1511:
1507:
1506:
1504:
1501:
1497:
1490:
1486:
1485:
1481:
1479:
1476:
1475:
1473:
1470:
1466:
1459:
1455:
1454:
1450:
1447:
1443:
1442:
1438:
1437:
1435:
1432:
1428:
1422:
1418:
1415:
1413:
1411:
1407:
1404:
1396:
1393:
1388:
1385:
1384:
1383:
1377:
1372:
1367:
1363:
1359:
1354:
1350:
1343:
1338:
1336:
1331:
1329:
1324:
1323:
1320:
1308:
1305:
1303:
1300:
1298:
1295:
1293:
1290:
1288:
1285:
1283:
1280:
1278:
1275:
1273:
1270:
1269:
1267:
1263:
1253:
1250:
1249:
1246:
1240:
1237:
1235:
1234:Donna Mansell
1232:
1230:
1227:
1225:
1224:Alexis Carrel
1222:
1221:
1219:
1215:
1209:
1206:
1205:
1203:
1199:
1193:
1190:
1189:
1187:
1183:
1177:
1174:
1172:
1169:
1167:
1164:
1162:
1159:
1158:
1156:
1152:
1146:
1145:Thomas Starzl
1143:
1141:
1138:
1136:
1133:
1132:
1130:
1126:
1120:
1117:
1115:
1112:
1110:
1109:Joseph Murray
1107:
1105:
1102:
1100:
1097:
1096:
1094:
1090:
1084:
1081:
1079:
1078:Richard Lower
1076:
1074:
1071:
1069:
1066:
1064:
1061:
1060:
1058:
1054:
1051:
1047:
1041:
1038:
1036:
1033:
1029:
1026:
1025:
1024:
1021:
1017:
1014:
1013:
1012:
1009:
1008:
1006:
1002:
996:
993:
991:
988:
986:
983:
982:
980:
976:
970:
967:
965:
962:
960:
957:
955:
952:
950:
947:
945:
942:
940:
939:Anthony Nolan
937:
936:
934:
932:organizations
928:
922:
919:
917:
914:
912:
909:
907:
904:
902:
899:
897:
894:
892:
889:
887:
884:
882:
879:
877:
874:
873:
871:
863:
857:
854:
852:
849:
847:
844:
843:
841:
839:Complications
837:
831:
828:
826:
823:
821:
818:
817:
815:
813:
809:
803:
800:
798:
797:Skin grafting
795:
793:
792:Bone grafting
790:
789:
787:
785:
781:
775:
772:
770:
767:
765:
762:
760:
757:
755:
752:
750:
747:
743:
740:
739:
738:
735:
733:
730:
728:
725:
723:
720:
718:
715:
713:
710:
708:
705:
703:
700:
698:
695:
693:
690:
688:
685:
683:
680:
678:
675:
673:
670:
668:
665:
664:
662:
660:
656:
650:
647:
645:
642:
638:
635:
634:
633:
630:
629:
627:
623:
619:
612:
607:
605:
600:
598:
593:
592:
589:
576:
572:
571:
567:
566:
563:
559:
552:
548:
547:
543:
540:
539:
535:
533:
529:
528:
524:
520:
517:
516:
512:
508:
507:
504:
499:
495:
488:
479:
475:
470:
465:
461:
457:
453:
446:
443:
438:
434:
428:
425:
420:
416:
411:
406:
402:
398:
394:
387:
384:
379:
375:
371:
367:
363:
359:
352:
349:
342:
340:
336:
329:
327:
325:
321:
313:
311:
309:
303:
299:
289:
286:
278:
268:
264:
260:
254:
253:
249:
244:This section
242:
238:
233:
232:
226:
224:
222:
217:
215:
211:
207:
203:
199:
194:
192:
188:
184:
179:
177:
173:
168:
166:
162:
158:
154:
146:
144:
140:
133:
131:
129:
125:
122:occurring in
121:
116:
114:
109:
105:
101:
91:
85:
82:
80:
76:
72:
68:
64:
61:
57:
53:
49:
44:
40:
36:
31:
19:
2127:
2070:
2064:By infection
1945:
1944:
1926:
1887:
1873:
1851:development/
1779:Plasmacytoma
1733:
1721:
1707:
1690:
1678:
1666:
1660:By infection
1643:
1604:
1541:
1508:
1482:
1451:
1441:naive B cell
1439:
1400:development/
1161:Fikri Alican
1135:Fikri Alican
850:
568:
544:
536:
521:
509:
459:
455:
445:
436:
427:
400:
396:
386:
364:(1): 29â44.
361:
357:
351:
337:
333:
330:Epidemiology
317:
307:
304:
300:
296:
281:
275:January 2020
272:
257:Please help
245:
218:
195:
180:
169:
150:
141:
137:
117:
103:
99:
98:
1946:aggressive:
1919:MF+variants
1458:Mantle cell
1453:mantle zone
1239:Bruce Reitz
891:LifeSharers
869:departments
830:Organ trade
672:Bone marrow
187:ciclosporin
153:lymphocytes
38:Other names
2294:Categories
2022:peripheral
1519:Follicular
1349:Leukaemias
742:islet cell
712:Heartâlung
546:DiseasesDB
343:References
198:antibodies
183:tacrolimus
84:Immunology
56:Micrograph
2157:Lymphoid+
1927:indolent:
1910:Cutaneous
1751:Cutaneous
1529:GCB DLBCL
1524:Burkitt's
1353:lymphomas
1004:Countries
717:Intestine
570:eMedicine
541:: M9970/1
314:Treatment
246:does not
227:Diagnosis
120:lymphomas
79:Specialty
71:HES stain
60:bronchial
2305:Lymphoma
2264:leukemia
1822:leukemia
1817:lymphoma
1376:leukemia
1371:lymphoma
1282:Eye bank
1185:Pancreas
969:ORGANIZE
930:Advocacy
737:Pancreas
575:ped/2851
518:: D47.Z1
478:17468341
419:21521464
378:15660500
165:cytokine
113:lymphoma
2252:General
2159:myeloid
2121:T or NK
2092:NK cell
1446:CLL/SLL
682:Corneal
267:removed
252:sources
2096:(most
2072:HTLV-1
1964:Non-MF
1853:marker
1826:(most
1812:T cell
1484:CD11c+
1402:marker
1380:(most
1366:B cell
1092:Kidney
1049:People
901:NOD-Lb
774:Vagina
769:Uterus
764:Thymus
759:Spleen
722:Kidney
532:238.77
476:
417:
376:
191:T cell
176:T-cell
147:Causes
108:B cell
86:
63:biopsy
2019:Other
1889:CD30+
1635:CD138
1606:CD20+
1500:CD79a
1217:Other
1201:Penis
1128:Liver
1056:Heart
749:Penis
727:Liver
707:Heart
677:Brain
625:Types
551:34154
538:ICD-O
456:Blood
58:of a
2098:CD56
1992:CD30
1971:CD30
1859:TdT+
1803:T/NK
1668:KSHV
1644:see
1631:CD38
1622:PCDs
1586:CD30
1582:CD15
1557:MALT
1469:CD22
1410:TdT+
1387:CD20
1382:CD19
1154:Lung
949:DKMS
754:Skin
732:Lung
702:Head
697:Hand
692:Face
667:Bone
637:ABOi
527:9-CM
474:PMID
415:PMID
374:PMID
250:any
248:cite
214:OKT3
212:and
185:and
104:PTLD
41:PTLD
2129:EBV
1994:+:
1973:-:
1863:ALL
1838:CD8
1833:CD4
1828:CD3
1723:HIV
1709:HCV
1680:EBV
1584:+,
1431:CD5
1417:ALL
687:Eye
523:ICD
511:ICD
464:doi
460:110
405:doi
366:doi
261:by
210:ALG
206:ATG
2296::
1861::
1849:By
1637:+)
1633:+/
1626:PP
1588:+)
1578:RS
1398:By
1351:,
573::
549::
530::
515:10
472:.
458:.
454:.
435:.
413:.
401:11
399:.
395:.
372:.
362:56
360:.
208:,
130:.
115:.
69:.
2195:)
2186:(
2140:)
2136:/
2132:(
2100:)
2094:/
2079:)
2075:(
2051:)
2047:(
1901:)
1892:(
1882:)
1878:(
1869:)
1865:(
1840:)
1824:)
1819:,
1815:(
1742:)
1738:(
1730:)
1726:(
1675:)
1671:(
1629:(
1624:/
1613:)
1609:(
1601:)
1597:(
1580:(
1569:)
1550:(
1545:/
1536:)
1517:(
1512:/
1502:+
1491:)
1487:(
1471:+
1460:)
1456:(
1448:)
1444:(
1433:+
1423:)
1419:(
1389:)
1378:)
1373:,
1369:(
1341:e
1334:t
1327:v
610:e
603:t
596:v
525:-
513:-
503:D
480:.
466::
439:.
421:.
407::
380:.
368::
288:)
282:(
277:)
273:(
269:.
255:.
102:(
73:.
20:)
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
